| Literature DB >> 21749764 |
Seth O'Neal1, John Noh, Patricia Wilkins, William Keene, William Lambert, James Anderson, Jennifer Compton Luman, John Townes.
Abstract
Neurocysticercosis (NCC) is a parasitic infection of the central nervous system caused by Taenia solium larval cysts. Its epidemiology in cysticercosis-nonendemic regions is poorly understood, and the role of public health institutions is unclear. To determine the incidence of NCC and to pilot screening of household contacts for tapeworms, we conducted population-based active surveillance in Oregon. We screened for T. solium infection by examining hospital billing codes and medical charts for NCC diagnosed during January 1, 2006-December 31, 2009 and collecting fecal and blood samples from household contacts of recent case-patients. We identified 87 case-patients, for an annual incidence of 0.5 cases per 100,000 general population and 5.8 cases per 100,000 Hispanics. In 22 households, we confirmed 2 additional NCC case-patients but no current adult intestinal tapeworm infections. NCC is of clinical and public health concern in Oregon, particularly among Hispanics. Public health intervention should focus on family members because household investigations can identify additional case-patients.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21749764 PMCID: PMC3320238 DOI: 10.3201/eid/1706.101397
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Demographic and clinical characteristics of cysticercosis case-patients, Oregon, 2006–2009
| Characteristic | No. confirmed/presumptive (%), n = 72 | No. suspected (%), n = 15 | p value* |
|---|---|---|---|
| Demographic† | |||
| M | 46 (64) | 5 (33) | 0.04 |
| Foreign-born | 47 (65) | 4 (27) | 1.0 |
| Signs and symptoms | |||
| Seizures | 29 (40) | 4 (27) | 0.07 |
| Headache | 27 (38) | 3 (20) | |
| Focal neurologic deficit | 5 (7) | 1 (7) | |
| Altered mental status | 3 (4) | 3 (20) | |
| Traumatic injury | 2 (3) | 2 (13) | |
| Other | 6 (8) | 2 (13) |
|
| Lesions | |||
| 1 | 22 (31) | 2 (13) | 0.10 |
| 2–4 | 21 (29) | 9 (60) | |
|
| 29 (40) | 4 (27) |
|
| Lesion location | |||
| Parenchymal | 61 (85) | 15 (100) | 0.49 |
| Extraparenchymal | 3 (4) | 0 | |
| Mixed | 8 (11) | 0 |
|
| Lesion stage | |||
| Cystic only | 22 (31) | 1 (7) | 0.01 |
| Calcified only | 32 (44) | 13 (87) | |
| Mixed | 18 (25) | 1 (7) |
*By Fisher exact test. †Median age, y (interquartile range): confirmed/presumptive, 36 (28–43); suspected, 47 (35–66); p<0.01, Mann-Whitney test.
Incidence of confirmed and presumptive cysticercosis cases, Oregon, 2006–2009
| Variable | 2006, n = 14 | 2007, n = 18 | 2008, n = 14 | 2009, n = 26* | All cases, n = 72 |
|---|---|---|---|---|---|
| Hispanic, no. (%) | 13 (93) | 18 (100) | 14 (100) | 24 (92) | 69 (96) |
| Years since immigration, median (interquartile range) | 8 (5–10) | 6 (2–10) | 10 (8–17) | 10 (4–18) | 9 (4–15) |
| Annual incidence | |||||
| Cases/100,000 overall population | 0.4 | 0.5 | 0.4 | 0.7 | 0.5 |
| Cases/100,000 Hispanic population | 3.4 | 4.5 | 3.4 | 5.5 | 5.8 |
*Number of reported confirmed and presumptive cases during the active study year (2009) compared with prior years, p = 0.08 by Fisher exact test.
Region and country of orgin for the 55 cysticercosis case-patients for whom information was known, Oregon, 2006–2009
| Region | No. (%) case-patients | Country (no. case-patients) |
|---|---|---|
| Central America, Caribbean | 47 (85) | Mexico (40), Guatemala (5), Nicaragua (1), Cuba (1) |
| North America | 3 (5) | United States (3) |
| Southeast Asia | 2 (4) | Myanmar [Burma] (1), Thailand (1) |
| South America | 1 (2) | Ecuador (1) |
| Africa | 1 (2) | Cameroon (1) |
| Europe | 1 (2) | Germany (1) |
Demographic and clinical characteristics of case-patients with investigated and noninvestigated cysticercosis , Oregon, 2006–2009*
| Characteristic† | Eligible for household investigation | No. (%) not eligible, n = 40 | p value‡ | |
|---|---|---|---|---|
| No. (%) investigated, n = 22 | No. (%) not Investigated, n = 10 | |||
| Male sex | 14 (64) | 9 (90) | 23 (58) | 0.16 |
| Lesions | ||||
| 1 | 6 (27) | 2 (20) | 14 (35) | 0.55 |
| >1 | 16 (73) | 8 (80) | 26 (65) |
|
| Lesion location | ||||
| Parenchymal | 17 (77) | 9 (90) | 35 (88) | 0.21 |
| Extraparenchymal | 2 (9) | 1 (10) | 0 | |
| Mixed | 3 (14) | 0 | 5 (13) |
|
| Lesion stage | ||||
| Cystic | 6 (27) | 1 (10) | 15 (38) | 0.15 |
| Calcified | 8 (36) | 8 (80) | 16 (40) | |
| Mixed | 8 (36) | 1 (10) | 9 (23) |
|
| EITB LLGP positive | 9 (41) | – | – | |
*EITB LLGP, enzyme-linked immunoelectrotransfer blot for antibodies against lentil lection–bound glycoprotein of Taenia solium cysts. †Median age, y (interquartile range): investigated, 31 (28–37); not investigated, 42 (35–57); not eligible, 35 (25–43); p = 0.15 by Kruskal-Wallis χ2 test. ‡By Fisher exact test.
| 1. The activity supported the learning objectives. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |
| 2. The material was organized clearly for learning to occur. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |
| 3. The content learned from this activity will impact my practice. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |
| 4. The activity was presented objectively and free of commercial bias. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |